The present technology is generally directed to shape memory actuators for adjustable shunting systems.
Implantable shunting systems are widely used to treat a variety of patient conditions by shunting fluid from a first body region/cavity to a second body region/cavity. The flow of fluid through the shunting sy stems is primarily controlled by the pressure gradient across the shunt lumen and the geometry (e.g., size) of the shunt lumen. One challenge with conventional shunting systems is selecting the appropriate geometry of the shunt lumen for a particular patient. A lumen that is too small may not provide enough therapy to the patient, while a lumen that is too large may create new issues in the patient. Despite this, most conventional shunts cannot be adjusted once they have been implanted. Accordingly, once the system is implanted, the therapy provided by the shunting system cannot be adjusted or titrated to meet the patient's individual needs.
As a result of the above, shunting systems with adjustable lumens have recently been proposed to provide a more personalized or titratable therapy. Such systems enable clinicians to titrate the therapy to an individual patient's needs, as well as adjust the therapy over time as the patient's disease changes. Adjustable shunting systems, however, generally require a power source (e.g., energy) to drive the adjustments. For example, the shunting system may include an implanted energy storage component such as a battery for storing energy that can subsequently be released to adjust a geometry of the shunt. However, depending on where the shunting system is positioned, the size of, and thus the storage capacity of, an implanted energy storage component may be limited. Accordingly, a need exists to provide adjustable shunting systems that can be adjusted using as little energy as possible.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily drawn to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the component is necessarily transparent. Components may also be shown schematically.
The present technology is directed to adjustable shunting systems having shape memory actuators and associated systems and methods. In some embodiments, for example, the present technology provides an adjustable shunting system having a first region and a second region. The first region includes a shunting element configured to extend between a first body region and a second body region. The second region is coupled to the first region and includes a shape memory actuator having a plurality of struts proximate the shunting element and a plurality of projections extending from the plurality of struts. A lumen extends through the first region and the second region between a first orifice and a second orifice. In operation, the shape memory actuator can be used to adjust a geometry of the lumen, the first orifice, and/or the second orifice in vivo to adjust the flow of fluid through the shunting system. Of note, the system is configured such that (1) mechanical strain in the shape memory actuator is concentrated in the struts, and (2) resistive heating preferentially occurs in the struts and not the projections, e.g., because the projections are not electrically in series with the struts. As described in detail herein, such a configuration is expected to advantageously reduce the energy requirements needed to actuate the shape memory actuator and, therefore, the energy requirements needed to adjust flow through the shunting system.
Shape memory actuators can be used to make in vivo adjustments to a geometry of an implanted shunting system. For example, shape memory actuators can be thermally actuated by heating at least a portion of the actuator to induce a geometric change in the actuator, which can be translated into a geometric change in the shunt lumen and/or lumen orifice. Examples of shape memory actuators and adjustable shunting systems utilizing shape memory actuators are described in U.S. patent application Ser. No. 17/016,192, filed Sep. 9, 2020, and International Patent Application No. PCT/US2020/063360, filed Dec. 4, 2020, the disclosures of which are incorporated by reference herein in their entireties.
To actuate shape memory actuators, an energy storage component (e.g., a battery, capacitor, etc.) in electrical communication with the shape memory actuator can release stored energy in the form of electrical current. The electrical current can flow through and resistively heat the shape memory actuator. If the shape memory actuator is heated above a “transition temperature,” a material phase change occurs (e.g., the shape memory actuator transitions from a low-temperature martensitic material state to a high-temperature R-phase or austenitic material state). The amount of energy required to resistively heat the actuator above its transition temperature depends on a number of factors, including the mass, resistance, and transition temperature of the actuator. Moreover, the amount of energy that can be stored by the energy storage components may be limited based the size of the energy storage component, which itself may be limited by patient anatomy. It is therefore beneficial to reduce/minimize the amount of energy required to resistively heat the actuator or targeted portions of the actuator above its transition temperature to ensure the energy storage component can store sufficient energy to actuate the actuator for a desired period of operation. In some embodiments, the energy that enables an actuation of a shape memory actuator is applied directly (e.g., from a source outside of the body) to the actuator or to an electrical circuit in electrical communication with the actuator without the use of an implanted energy storage component. In such examples, reducing/minimizing the amount of energy required to resistively heat the actuator or targeted portions of the actuator will nevertheless be beneficial because it will accelerate an adjustment procedure and perhaps increase the safety and cost-effectiveness of the procedure.
The present technology therefore provides shape memory actuators that are designed to be actuated using relatively low amounts of energy. For example, as described in detail below, the shape memory actuators are designed such that thermo-mechanically-recoverable strain in the actuator is concentrated in a select region of the actuator rather than being distributed evenly throughout the actuator. As a result, only the portion(s) of the actuator having the concentrated recoverable strain needs to be resistively heated in order to cause the actuator to undergo a complete, or nearly complete, geometry change related to the shape memory effect. In addition, the actuator is designed such that when an electrical current is applied to the actuator, the electrical current flows preferentially through regions of the actuator experiencing strain, thereby preferentially heating these portions of the actuator. Without being bound by theory, this is expected to reduce the amount of energy required to actuate the shape memory actuator.
The terminology used in the description presented below is intended to be interpreted in its broadest reasonable manner, even though it is being used in conjunction with a detailed description of certain specific embodiments of the present technology. Certain terms may even be emphasized below; however, any terminology intended to be interpreted in any restricted manner will be overtly and specifically defined as such in this Detailed Description section. Additionally, the present technology can include other embodiments that are within the scope of the claims but are not described in detail with respect to
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present technology. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features or characteristics may be combined in any suitable manner in one or more embodiments.
As used herein, the use of relative terminology, such as “about”, “approximately”, “substantially” and the like refer to the stated value plus or minus ten percent. For example, the use of the term “about 100” refers to a range of from 90 to 110, inclusive. In instances in which the context requires otherwise and/or relative terminology is used in reference to something that does not include a numerical value, the terms are given their ordinary meaning to one skilled in the art.
As used herein, the term “geometry” can include the size and/or the shape of an element. Accordingly, when the present disclosure describes a change in geometry, it can refer to a change in the size of an element (e.g., moving from a smaller circle to a larger circle), a change in the shape of an element (e.g., moving from a circle to an oval), and/or a change in the shape and size of an element (e.g., moving from a smaller circle to a larger oval). In various embodiments, “geometry” refers to the relative arrangements and/or positions of elements in the respective system.
The first region 110 is configured to at least partially interface with patient tissue when the system 100 is implanted in a patient. For example, the first region 110 can include a shunting element or frame 112 that can traverse patient tissue (e.g., the septal wall) when implanted in the patient. The shunting element 112 has a first end portion 112a that is in fluid communication with the first body region (e.g., the left atrium) when the system 100 is implanted and a second end portion 112b that is in fluid communication with the second body region (e.g., the right atrium) when the system 100 is implanted. The lumen 102 extends through the shunting element 112, permitting fluid to flow between the first end portion 112a and the second end portion 112b through an interior of the shunting element 112. In some embodiments, the shunting element 112 includes a first membrane 114 at least partially encasing or integral with the shunting element 112. The first membrane 114 can be composed of a biocompatible and/or anti-thrombogenic material, such as PTFE, ePTFE, PET (e.g., Dacron), silicone, urethane, nylon, or the like.
The second region 120 can have a generally tapered (e.g., conical or hyperboloid) shape extending from the first region 110 to an orifice 124 (e.g., an outflow aperture or an inflow aperture). The lumen 102 extends through the second region 120 and fluidly couples an interior of the second region 120 with the interior of the first region 110. Accordingly, when the system 100 is implanted in a patient, fluid may flow into the lumen 102 via an orifice (not shown) at the first end portion 112a, through the lumen 102 extending through both the first region 110 and the second region 120, and out of the orifice 124 defined by the second region 120. In other embodiments, the direction of fluid flow may be reversed, such that fluid flows into the lumen 102 via the orifice 124. In some embodiments, the second region 120 is configured to at least partially extend into the second body region (e.g., the right atrium) when the system 100 is implanted in a patient. Accordingly, at least a portion of the second region 120 may be out of contact with patient tissue (e.g., extending into/suspended in the patient's right atrium). Moreover, although shown as having the second region 120 coupled to the second end portion 112b of the shunting element 112, in other embodiments the second region 120 can be coupled to the first end portion 112a of the shunting element 112 such that the second region 120 extends into the first body region (e.g., the left atrium).
The second region 120 includes an actuator 130 and a second membrane 122. As described in detail below with respect to
The system 100 can include other components not illustrated in
The strut portions of the actuation members 231 therefore collectively comprise a plurality of struts 232 and the projection portions of the actuation members 231 therefore collectively comprise a plurality of projections 234. As illustrated, the plurality of struts 232 form a partially curved annular, conical, hyperbolic, or ring-like shape, and the plurality of projections extend at least partially radially inward from the plurality of struts 232 to form the conical/funnel shape. Although the struts 232 are shown as having a “zig-zag” pattern, the struts 232 can also have a diamond-shaped or other suitable pattern while still having the partially curved annular shape. A proximal end portion 236 of the struts can be secured to the shunting element 112 (
The projections 234 are elongated fingers/levers that extend from a distal end portion of the struts 232. In the embodiment shown in
The struts 232 and the projections 234 may have different dimensions. For example, the struts 232 can have an axial cross-sectional area that is less than an axial cross-sectional area of the projections 234.
The cross-sectional area of the struts 232 can be at least 10% smaller than the cross-sectional area of the projections 234. For example, the cross-sectional area of the struts 232 can be at least 10% smaller than, at least 20% smaller than, at least 50% smaller than, at least 75% smaller than, or at least 99% smaller than the cross-sectional area of the projections 234. Such an arrangement can facilitate resistive heating of the struts 232 while maintaining desirable mechanical properties associated with relatively larger projections 234. In some embodiments, the cross-sectional area of the struts 232 can vary along a length of the struts 232, but is nevertheless generally smaller than the cross-sectional area of the projections 234. Likewise, the cross-sectional area of the projections 234 can vary along a length of the projections 234, but is nevertheless generally larger than the cross-sectional area of the struts 232. As described in detail below, struts 232 that have a small cross-section beneficially increases the electrical resistance of the struts 232 relative to struts with a larger cross-section, which can assist with resistive heating. In some embodiments (e.g., those driven by a current source) a smaller cross-section strut can increase an electrical current density in the struts 232 during resistive heating of the actuator 130.
In embodiments in which the actuator 130 is fabricated as a unitary structure, the actuator 130 can be initially fabricated with uniform dimensions (e.g., the cross-sectional area of the struts 232 is equal to the cross-sectional area of the projections 234). The struts 232 can then be reduced in cross-sectional area relative to the projections 234 during a manufacturing operation (e.g., localized grinding, microblasting, milling, ablating, cutting, chemical etching electro-polishing, etc.). In other embodiments, the actuator 130 is initially fabricated such that the struts 232 and the projections 234 have different cross-sectional areas without the need for the cross-sectional-reduction manufacturing operation.
The actuator 130 can be configured to adjust a geometry (e.g., dimension) of the orifice 124. In particular, the actuator 130 can be at least partially composed of a shape memory material, such as nitinol. The actuator 130 (or a portion thereof) can therefore be transitionable between a first material phase or state (e.g., martensitic, R-phase, a composite state between martensitic and R-phase, etc.) and a second material phase or state (e.g., austenitic, R-phase, a composite state between austenitic and R-phase, etc.) by heating the actuator 130 above its transition temperature. In the first material state, the actuator 130 may be deformable (e.g., plastic, compressible, expandable, etc.). In the second material state, the actuator 130 may exhibit superelastic properties and/or have a preference toward a specific preferred geometry (e.g., original geometry, fabricated geometry, heat-set geometry, shape-set geometry, etc.). If the actuator 130 is deformed relative to its preferred geometry when in the first material state, heating the actuator 130 above its transition temperature causes the actuator 130 to move to and/or toward its preferred geometry as it transitions to its second material state. In some embodiments, the actuator 130 is fabricated to have a transition temperature greater than average body temperature such that, during and after implantation in a patient, the actuator 130 remains in the first material phase.
From the second configuration P2, the orifice 124 can be reduced in size by heating the actuator 130 (or a portion thereof) above its transition temperature. Because the actuator 130 is deformed relative to its preferred geometry, heating the actuator 130 above its transition temperature causes the actuator 130 to move to and/or toward its preferred geometry. This draws the distal end portion 238 of the projections 234 radially inward, reducing the size of the orifice 124. For example, heating the actuator 130 above its transition temperature can cause the orifice 124 to assume a third configuration P3 having a third diameter D3 that is less than the second diameter D2. In some embodiments, the third diameter D3 may be the same as the first diameter D1, although in other embodiments the third diameter D3 is greater than or less than the first diameter D1. Although only three configurations are shown, in some embodiments the actuator 130 may be manipulated into other configurations having different orifice 124 dimensions. In some embodiments, heating the actuator 130 (or a portion thereof) can further increase the size of orifice 124—e.g., the third configuration P3 is associated with a third diameter D3 that is larger than both D2 and D1.
In some embodiments, the actuator 130 is deformed relative to its preferred geometry when coupled to the shunting element 112 or other component of the system 100 (
The actuator 130 can be configured to reduce/minimize the energy requirements needed for actuation. For example, the actuator 130 can be configured such that, when coupled to the shunting element 112 (
Because the strain is concentrated in the struts 232, only the struts 232 need to be heated above the transition temperature to move the actuator toward its preferred geometry. In other words, because there is little to no strain in the projections 234, the projections 234 need not be heated above the transition temperature, since there is little to no deformation in the projections 234 to be recovered. Without being bound by theory, concentrating the strain to a particular region of the actuator 130 is expected to provide several advantages relative to an actuator having strain distributed throughout a majority of its structure. For example, concentrating strain in the struts 232 reduces the volume of material that must be heated above a transition temperature in order to actuate the actuator 130. In turn, when coupled with systems and methods that enable preferential heating of the strained regions of the structure, this reduces the energy requirements needed to actuate the actuator 130, as limited to no energy would need to be delivered to unstrained areas. This is of particular importance for implanted medical devices having a finite energy storage capacity and/or energy receiving capabilities.
Even though the strain is concentrated in the struts 232, inducing a material phase change (and a corresponding geometric change) in the struts 232 moves the projections 234 because the projections 234 are coupled to (e.g., integral with) the struts 232. In fact, due to their elongated length, a relatively small angular movement in the struts 232 can be translated into a relatively larger angular movement of the distal end portions 238 of the projections 234. Because the distal end portions 238 define the orifice 124, a relatively small geometric change in the struts 232 can thus impart a relatively larger geometric change in the orifice 124.
In addition to concentrating strain in the struts 232, the actuator 130 can be configured such that the regions with higher strain (e.g., the struts 232) also have a higher degree of resistive heating when a current is applied to the actuator. For example, the projections 234 can be designed such that they are effectively not electrically in series with the struts 232. As a consequence of this, within embodiments, electrical current applied to the actuator will flow primarily or entirely through sections of the actuator 130 that are adjacent (e.g., proximate) to struts 232, thereby imparting the greatest degree of resistive heating at the struts 232. Of course, the projections 234 may still be subject to some degree of conductive heating resulting from the resistive heating of the adjacent struts 232, but such conductive heating does not significantly affect the energy output required to actuate the actuator 130.
The different degree of resistive heating induced in the struts 232 and the projections 234 when an electrical current is applied to the actuator 130 can be achieved by manipulating a variety of factors. In some embodiments, the actuator 130 can be comprised of a single material. In such embodiments, the actuator 130 can be designed such that the struts 232 are electrically in series with one another and that each of the projections 234 is not in electrical series with the struts 232 or other portions of the actuator 130. For example, individual struts of the plurality of struts 232 can be electrically coupled in series, while the plurality of projections 234 are not in electrical series with the plurality of struts 232. In such a configuration, each projection 234 can effectively terminate in an open circuit, preventing substantial current flow (and therefore, meaningful resistive heating) along the projection 234. Within embodiments as described, an electrical power source (e.g., a voltage source, a current source, etc.) can have contact with the actuator 130 in portions that are proximate to struts 232.
In some embodiments, the actuator 130 can be constructed of struts 232 that are comprised of an electrically conductive shape memory material and projections 234 that are comprised of a relatively non-conductive material, such as a plastic. The struts 232 and the projections 234 can be joined in a manufacturing process (e.g., using welding, sutures, adhesives, press-fits, and/or other techniques known to those skilled in the art). In such embodiments, the electrical resistance of the struts 232 can be lower than that of the projections 234, however, without being bound by theory, it is expected that since the projections 234 are essentially non-conductive that they will force substantially all current applied to the actuator 130 to flow through the struts 232. In such a design, the flow of current through the system can additionally or alternatively be dictated by the configuration of the actuator (e.g., whether struts and projections are electrically in series), as described above. In embodiments as described, the plurality of struts is constructed such that the struts are in electrical continuity with one another. In some embodiments, both the struts 232 and the projections 234 are electrically conductive, but are joined during manufacturing through a non-conductive joint that isolates the projections 234 from an electrical circuit that includes the plurality of struts 232. In each of the foregoing examples, the actuator 130 design effectively removes the projections 234 from an electrical circuit that is used to heat the actuator 130, meaning that all or substantially all energy applied to the actuator 130 will travel through struts 232 (which as previously described contains substantially all the strain in the component). As such, the energy requirements are reduced relative to embodiments in which the electrical current must flow through the entirety of actuator 130 in order to elevate the temperature of the struts 232.
Although described in the context of struts and projections, the shape memory actuators described herein can include other suitable designs that (1) concentrate mechanical strain in the shape memory actuator in a particular region or portion of the actuator, and (2) cause resistive heating of the actuator to preferentially occur in said particular region or portion with the strain. For example,
The actuator 430 can be composed of a shape-memory wire or filament (e.g., nitinol wireform) embedded within or otherwise affixed to the membrane 422, which may be the same or generally similar to the membrane 122 described with reference to
The actuator 430 can be configured such that any mechanical strain induced by deforming the actuator 430 relative to its preferred geometry preferentially builds in the curved regions 436, e.g., relative to any mechanical strain induced in the first petals 432 and the second petals 434. That is, when the actuator 430 is deformed relative to its preferred geometry (e.g., via balloon expansion, catheterization, or the like), the actuator 430 bends or hinges at the curved regions 436. As a result, the geometry of the first petals 432 and the second petals 434 remains generally unchanged, but the spatial position of the second petals 434 relative to the first petals 432 and/or relative to each other may change (e.g., thereby changing a dimension of the orifice 424). Likewise, when a previous deformation of the actuator 430 is thermo-elastically recovered (e.g., via actuating the actuator 430), the thermoelastic recovery occurs primarily in the curved regions 436. Because the curved regions 436 are coupled to the first petals 432 and the second petals 436, this recovery may cause the second petals 434 to move relative to the first petals 432 and change a dimension of the orifice 424. This above operation is similar to concentrating mechanical strain in the struts 232 to cause a corresponding movement of the projections 234, described above with respect to the actuator 130.
The actuator 430 can further be configured such that the curved regions 436 can be preferentially heated relative to the first petals 432 and/or the second petals 434 to provide a more efficient shape memory actuator. For example, the actuator 430 can include a series of electrical bridges 438 extending between the curved regions 436 (
As described above, and regardless of whether the actuator 130 (
However, in some embodiments, the present technology provides systems having a “bi-directional shape memory adjustment mechanism” in which a shape-memory effect can be utilized to both increase and decrease a diameter or other dimension of a system orifice or lumen. For example,
The actuation assembly 500 includes a first actuator 530 and a second actuator 540. The first actuator 530 can be generally similar to the actuator 130 described with respect to
To form the actuation assembly 500, the first actuator 530 is coupled to the second actuator 540, as shown in
Coupling the first actuator 530 and the second actuator 540 therefore induces strain in both the first actuator 530 and the second actuator 540. As described above with respect to the actuator 130, this strain can be concentrated in the struts 532 and 542, with little to no strain in the projections 534 and 544 (e.g., by virtue of the struts 532, 542 operating as a “hinge”). Because strain exists in both actuators, the actuators can be selectively (e.g., independently) heated to thermally recover the strain and induce a geometric change therein.
The first actuator 530 and the second actuator 540 are configured to work in opposition. For example, to increase a diameter of the orifice, the second actuator 540 can be selectively actuated (e.g., by resistively heating the struts 542 above a transition temperature). This induces a material phase change in the struts 542 (e.g., transitioning from a martensitic material state or from an R-phase to an R-phase or austenitic material state) and drives the second actuator 540 toward its preferred geometry, as shown in
To decrease a diameter of the orifice, the first actuator 530 can be selectively actuated (e.g., by resistively heating the struts 532 above a transition temperature). This induces a material phase change in the struts 532 and drives the first actuator 530 toward its preferred geometry, as shown in
To facilitate the selective and independent actuation of the first actuator 530 and the second actuator 540, the first actuator 530 and the second actuator 540 can be electrically and/or thermally isolated. For example, the first actuator 530 may form a first electrical circuit for resistively heating the struts 532, and the second actuator 540 may form a second electrical circuit for resistively heating the struts 542. Additional details regarding operation of opposing “bi-directional” shape memory actuation assemblies are described in U.S. patent application Ser. No. 17/016,192, previously incorporated by reference herein.
As one of skill in the art will appreciate from the disclosure herein, various components of the systems described above can be omitted without deviating from the scope of the present technology. Likewise, additional components not explicitly described above may be added to the systems without deviating from the scope of the present technology. Accordingly, the present technology is not limited to the configurations expressly identified herein, but rather encompasses variations and alterations of the described systems.
For example, although primarily described as having a first section (e.g., the section 110 in
Moreover, in some embodiments the projections of an actuator do not terminate at an orifice, and therefore the terminal/distal ends of the projections may not define an orifice size or geometry directly. For example, some embodiments can use a cone-shaped actuator similar or identical to that shown in
The technology described herein can be used in adjustable shunting systems adapted for use at a variety of anatomical locations. For example, in some embodiments the adjustable shunting systems can be interatrial shunts configured to extend through a septal wall and shunt blood from a left atrium to a right atrium. In other embodiments, the adjustable shunting systems can be positioned at another location, such as to provide blood flow between other chambers and passages of the heart or other parts of the cardiovascular system. For example, the systems described herein can be used to shunt blood between the left atrium and the coronary sinus, or between the right pulmonary vein and the superior vena cava, or from the right atrium to the left atrium. In yet other embodiments, the adjustable shunting systems may be used to shunt fluid between other body regions.
Several aspects of the present technology are set forth in the following examples:
1. An adjustable shunting system, comprising:
2. The adjustable shunting system of example 1 wherein the shape memory actuator is configured such that, when an electrical current is applied to the shape memory actuator, the plurality of struts experiences higher resistive heating than the plurality of projections.
3. The adjustable shunting system of example 2 wherein:
4. The adjustable shunting system of any of examples 1-3 wherein the plurality of struts have an axial cross-sectional area smaller than an axial cross-sectional area of the plurality of projections.
5. The adjustable shunting system of any of examples 1-4 wherein, when electrical current flows through the shape memory actuator, the plurality of struts have a higher electrical current density than the plurality of projections.
6. The adjustable shunting system of any of examples 1-5 wherein the plurality of struts form an annular structure, and wherein the plurality of projections extend from the annular structure to form a conical structure.
7. The adjustable shunting system of any of examples 1-6 wherein the plurality of struts are slightly curved.
8. The adjustable shunting system of any of examples 1-7 wherein the plurality of projections are straight.
9. The adjustable shunting system of any of examples 1-8 wherein, when actuated, the shape memory actuator is configured to bend at the struts.
10. The adjustable shunting system of any of examples 1-9 wherein a first end portion of the plurality of projections is coupled to the plurality of struts, and wherein a second end portion of the plurality of struts defines the first orifice.
11. The adjustable shunting system of any of examples 1-10 wherein the plurality of projections are substantially unstrained when the actuator is deformed relative to its preferred geometry.
12. The adjustable shunting system of any of examples 1-11 wherein the plurality of struts and the plurality of projections comprise a unitary structure.
13. The adjustable shunting system of any of examples 1-12 wherein the shape memory actuator is a first shape memory actuator, the struts are first struts, and the projections are first projections, and wherein the second region further comprises:
14. The adjustable shunting system of example 13 wherein the first shape memory actuator is configured to increase a dimension of the lumen, the first orifice, and/or the second orifice, and wherein the second shape memory actuator is configured to decrease a dimension of the lumen, the first orifice, and/or the second orifice.
15. The adjustable shunting system of example 13 or example 14 wherein the first shape memory actuator is coupled to the second shape memory actuator, and wherein, when coupled, at least one of the first shape memory actuator and the second shape memory actuator is deformed relative to their respective preferred geometries.
16. The adjustable shunting system of any of examples 1-15 wherein the system is configured such that, when the system is implanted in a patient:
17. An adjustable shunting system, comprising:
18. The adjustable shunting system of example 17 wherein:
19. The adjustable shunting system of example 17 or example 18 wherein the plurality of struts are formed from a first material having a first conductivity, and wherein the plurality of projections are formed from a second material having a second conductivity less than the first conductivity.
20. The adjustable shunting system of any of examples 17-19 wherein the plurality of struts are electrically isolated from the plurality of projections.
21. The adjustable shunting system of any of examples 17-20 wherein the plurality of struts have an axial cross-sectional area smaller than an axial cross-sectional area of the plurality of projections.
22. The adjustable shunting system of example 21 wherein the axial cross-sectional area of the plurality of struts is at least 50% smaller than the axial cross-sectional area of the plurality of projections.
23. The adjustable shunting system of example 21 or example 22 wherein individual struts have a constant cross-sectional area along an axial length thereof.
24. The adjustable shunting system of example 21 or example 22 wherein individual struts have a variable cross-sectional area along an axial length thereof.
25. The adjustable shunting system of any of examples 17-24 wherein, when electrical current flows through the shape memory actuator, the plurality of struts have a higher electrical current density than the plurality of projections.
26. The adjustable shunting system of any of examples 17-25 wherein, when actuated, the shape memory actuator is configured to bend at the struts.
27. The adjustable shunting system of any of examples 17-26 wherein the system is configured such that any strain in the shape memory actuator is concentrated in the plurality of struts.
28. The adjustable shunting system of example 27 wherein the plurality of struts are slightly curved, and wherein the plurality of projections are straight.
29. The adjustable shunting system of example 27 wherein the plurality of struts form an annular structure, and wherein the plurality of projections extend from the annular structure to form a conical structure.
30. The adjustable shunting system of any of examples 17-29 wherein the plurality of struts and the plurality of projections form a unitary structure.
31. The adjustable shunting system of any of examples 17-30 wherein the system is configured such that, when the system is implanted in a patient:
32. The adjustable shunting system of example 31 wherein the first body region is a left atrium of a patient's heart and the second body region is a right atrium of the patient's heart.
33. An adjustable shunting system, comprising:
34. The adjustable shunting system of example 33 wherein the strut portions are slightly curved, and wherein the projection portions are straight.
35. The adjustable shunting system of example 33 or example 34 wherein the individual actuation members have a “Y” shape.
36. The adjustable shunting system of any of examples 33-35 wherein the individual actuation members are arranged side-by-side to form the conical shape.
37. The adjustable shunting system of any of examples 33-36 wherein, when actuated, the shape memory actuator is configured to bend at the strut portions.
38. The adjustable shunting system of any of examples 33-37 wherein the individual actuation members are integral with one another such that the shape memory actuator is a unitary structure.
39. An adjustable shunting system, comprising:
40. An adjustable shunting system, comprising:
41. The adjustable shunting system of example 40 wherein the shape memory actuator at least partially defines the lumen, the first orifice, and the second orifice.
Conclusion
Embodiments of the present disclosure may include some or all of the following components: a battery, supercapacitor, or other suitable power source; a microcontroller, FPGA, ASIC, or other programmable component or system capable of storing and executing software and/or firmware that drives operation of an implant; memory such as RAM or ROM to store data and/or software/firmware associated with an implant and/or its operation; wireless communication hardware such as an antenna system configured to transmit via Bluetooth, Wi-Fi, or other protocols known in the art; energy harvesting means, for example a coil or antenna which is capable of receiving and/or reading an externally-provided signal which may be used to power the device, charge a battery, initiate a reading from a sensor, or for other purposes. Embodiments may also include one or more sensors, such as pressure sensors, impedance sensors, accelerometers, force/strain sensors, temperature sensors, flow sensors, optical sensors, cameras, microphones or other acoustic sensors, ultrasonic sensors, ECG or other cardiac rhythm sensors, SpO2 and other sensors adapted to measure tissue and/or bloodgas levels, blood volume sensors, and other sensors known to those who are skilled in the art. Embodiments may include portions that are radiopaque and/or ultrasonically reflective to facilitate image-guided implantation or image guided procedures using techniques such as fluoroscopy, ultrasonography, or other imaging methods. Embodiments of the system may include specialized delivery catheters/systems that are adapted to deliver an implant and/or carry out a procedure. Systems may include components such as guidewires, sheaths, dilators, and multiple delivery catheters. Components may be exchanged via over-the-wire, rapid exchange, combination, or other approaches.
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise forms disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
Unless the context clearly requires otherwise, throughout the description and the examples, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense, as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including but not limited to.” As used herein, the terms “connected,” “coupled,” or any variant thereof, means any connection or coupling, either direct or indirect, between two or more elements; the coupling of connection between the elements can be physical, logical, or a combination thereof. Additionally, the words “herein,” “above,” “below,” and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of this application. Where the context permits, words in the above Detailed Description using the singular or plural number may also include the plural or singular number respectively. As used herein, the phrase “and/or” as in “A and/or B” refers to A alone, B alone, and A and B. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application is a 35 U.S.C. § 371 U.S. National Phase application of International Patent Application No. PCT/US2022/019374, filed Mar. 8, 2022, which claims the benefit of U.S. Provisional Application No. 63/158,508, filed Mar. 9, 2021, the disclosures of which are incorporated herein by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/019374 | 3/8/2022 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2022/192280 | 9/15/2022 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
4601309 | Chang | Jul 1986 | A |
4662355 | Pieronne et al. | May 1987 | A |
4705507 | Boyles | Nov 1987 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4979955 | Smith | Dec 1990 | A |
4995857 | Arnold | Feb 1991 | A |
5186431 | Tamari | Feb 1993 | A |
5197978 | Hess | Mar 1993 | A |
5267940 | Moulder | Dec 1993 | A |
5290227 | Pasque | Mar 1994 | A |
5312341 | Turi | May 1994 | A |
5326374 | Ilbawi et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5334217 | Das | Aug 1994 | A |
5409019 | Wilk | Apr 1995 | A |
5429144 | Wilk | Jul 1995 | A |
5500015 | Deac | Mar 1996 | A |
5531759 | Kensey et al. | Jul 1996 | A |
5556386 | Todd | Sep 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5597377 | Aldea | Jan 1997 | A |
5611338 | Gallup | Mar 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
5655548 | Nelson et al. | Aug 1997 | A |
5662711 | Douglas | Sep 1997 | A |
5702412 | Popov et al. | Dec 1997 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5741297 | Simon | Apr 1998 | A |
5795307 | Krueger | Aug 1998 | A |
5810836 | Hussein et al. | Sep 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5916193 | Stevens et al. | Jun 1999 | A |
5941850 | Shah et al. | Aug 1999 | A |
5944019 | Kundson et al. | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
6039759 | Carpentier et al. | Mar 2000 | A |
6077298 | Tu et al. | Jun 2000 | A |
6120534 | Ruiz | Sep 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6165188 | Saadat et al. | Dec 2000 | A |
6165209 | Patterson et al. | Dec 2000 | A |
6210318 | Lederman | Apr 2001 | B1 |
6217541 | Yu | Apr 2001 | B1 |
6240322 | Peterfeso et al. | May 2001 | B1 |
6242762 | Brown et al. | Jun 2001 | B1 |
6254564 | Wilk et al. | Jul 2001 | B1 |
6260552 | Mortier et al. | Jul 2001 | B1 |
6270526 | Cox | Aug 2001 | B1 |
6277078 | Porat et al. | Aug 2001 | B1 |
6302892 | Wilk | Oct 2001 | B1 |
6328699 | Eigler et al. | Dec 2001 | B1 |
6344022 | Jarvik | Feb 2002 | B1 |
6358277 | Duran | Mar 2002 | B1 |
6406422 | Landesberg | Jun 2002 | B1 |
6447539 | Nelson et al. | Sep 2002 | B1 |
6451051 | Drasler et al. | Sep 2002 | B2 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6468303 | Amplatz et al. | Oct 2002 | B1 |
6478776 | Rosenman et al. | Nov 2002 | B1 |
6491705 | Gifford, III et al. | Dec 2002 | B2 |
6514285 | Pinchasik | Feb 2003 | B1 |
6527698 | Kung et al. | Mar 2003 | B1 |
6544208 | Ethier et al. | Apr 2003 | B2 |
6562066 | Martin | May 2003 | B1 |
6572652 | Shaknovich | Jun 2003 | B2 |
6589198 | Soltanpour et al. | Jul 2003 | B1 |
6632169 | Korakianitis et al. | Oct 2003 | B2 |
6638303 | Campbell | Oct 2003 | B1 |
6641610 | Wolf et al. | Nov 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6685664 | Levin et al. | Feb 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6783499 | Schwartz | Aug 2004 | B2 |
6909920 | Lokhoff et al. | Jun 2005 | B2 |
6911043 | Myers et al. | Jun 2005 | B2 |
6926670 | Rich et al. | Aug 2005 | B2 |
7001409 | Amplatz | Feb 2006 | B2 |
7011095 | Wolf et al. | Mar 2006 | B2 |
7056294 | Khairkhahan et al. | Jun 2006 | B2 |
7149587 | Wardle et al. | Dec 2006 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7270675 | Chun et al. | Sep 2007 | B2 |
7294115 | Wilk | Nov 2007 | B1 |
7311690 | Burnett | Dec 2007 | B2 |
7311730 | Gabbay | Dec 2007 | B2 |
7317951 | Schneider et al. | Jan 2008 | B2 |
7389134 | Karicherla et al. | Jun 2008 | B1 |
7390310 | McCusker et al. | Jun 2008 | B2 |
7513908 | Lattouf | Apr 2009 | B2 |
7524329 | Rucker | Apr 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7524332 | Osborne et al. | Apr 2009 | B2 |
7608067 | Bonni | Oct 2009 | B2 |
7615010 | Najafi et al. | Nov 2009 | B1 |
7617001 | Penner et al. | Nov 2009 | B2 |
7634318 | Tran et al. | Dec 2009 | B2 |
7658747 | Forde et al. | Feb 2010 | B2 |
7699059 | Fonseca et al. | Apr 2010 | B2 |
7736327 | Wilk et al. | Jun 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7794473 | Tessmer et al. | Sep 2010 | B2 |
7806921 | Hoffman | Oct 2010 | B2 |
7860579 | Goetzinger et al. | Dec 2010 | B2 |
7892246 | Akin et al. | Feb 2011 | B2 |
7905901 | Corcoran et al. | Mar 2011 | B2 |
7922764 | Gordy et al. | Apr 2011 | B2 |
7938840 | Golden et al. | May 2011 | B2 |
7967769 | Faul et al. | Jun 2011 | B2 |
7988724 | Salahieh et al. | Aug 2011 | B2 |
8012198 | Hill et al. | Sep 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8043360 | McNamara et al. | Oct 2011 | B2 |
8070708 | Rottenberg et al. | Dec 2011 | B2 |
8091556 | Keren et al. | Jan 2012 | B2 |
8096959 | Stewart et al. | Jan 2012 | B2 |
8147545 | Avior | Apr 2012 | B2 |
8157860 | McNamara et al. | Apr 2012 | B2 |
8172896 | McNamara et al. | May 2012 | B2 |
8235916 | Whiting et al. | Aug 2012 | B2 |
8235933 | Keren et al. | Aug 2012 | B2 |
8246677 | Ryan | Aug 2012 | B2 |
8252042 | McNamara et al. | Aug 2012 | B2 |
8303511 | Eigler et al. | Nov 2012 | B2 |
8328751 | Keren et al. | Dec 2012 | B2 |
8348996 | Tuval et al. | Jan 2013 | B2 |
8398708 | Meiri et al. | Mar 2013 | B2 |
8460366 | Rowe | Jun 2013 | B2 |
8460372 | McNamara et al. | Jun 2013 | B2 |
8597225 | Kapadia | Dec 2013 | B2 |
8647381 | Essinger et al. | Feb 2014 | B2 |
8696611 | Nitzan et al. | Apr 2014 | B2 |
8740962 | Finch et al. | Jun 2014 | B2 |
8745845 | Finch et al. | Jun 2014 | B2 |
8747458 | Tuval et al. | Jun 2014 | B2 |
8752258 | Finch et al. | Jun 2014 | B2 |
8764848 | Callaghan et al. | Jul 2014 | B2 |
8882697 | Celermajer et al. | Nov 2014 | B2 |
8951223 | McNamara et al. | Feb 2015 | B2 |
9005155 | Sugimoto | Apr 2015 | B2 |
9034034 | Nitzan et al. | May 2015 | B2 |
9138213 | Amin et al. | Sep 2015 | B2 |
9180005 | Lashinski et al. | Nov 2015 | B1 |
9204842 | Mothilal et al. | Dec 2015 | B2 |
9205236 | McNamara et al. | Dec 2015 | B2 |
9232997 | Sugimoto et al. | Jan 2016 | B2 |
9277995 | Celermajer et al. | Mar 2016 | B2 |
9358371 | McNamara et al. | Jun 2016 | B2 |
9456812 | Finch et al. | Oct 2016 | B2 |
9610041 | Foster et al. | Apr 2017 | B2 |
9629715 | Nitzan et al. | Apr 2017 | B2 |
9642993 | McNamara et al. | May 2017 | B2 |
9649480 | Sugimoto et al. | May 2017 | B2 |
9681948 | Levi et al. | Jun 2017 | B2 |
9707382 | Nitzan et al. | Jul 2017 | B2 |
9713696 | Yacoby et al. | Jul 2017 | B2 |
9724499 | Rottenberg et al. | Aug 2017 | B2 |
9757107 | McNamara et al. | Sep 2017 | B2 |
9775636 | Fazio et al. | Oct 2017 | B2 |
9918856 | Favier et al. | Mar 2018 | B2 |
9937036 | Sugimoto et al. | Apr 2018 | B2 |
9943670 | Keren et al. | Apr 2018 | B2 |
9980815 | Nitzan et al. | May 2018 | B2 |
10045766 | McNamara et al. | Aug 2018 | B2 |
10076403 | Eigler et al. | Sep 2018 | B1 |
10188375 | McNamara et al. | Jan 2019 | B2 |
10207087 | Keren | Feb 2019 | B2 |
10251740 | Eigler et al. | Apr 2019 | B2 |
10292690 | Celermajer et al. | May 2019 | B2 |
10350384 | Farnan et al. | Jul 2019 | B2 |
10357357 | Levi et al. | Jul 2019 | B2 |
10368981 | Nitzan et al. | Aug 2019 | B2 |
10376359 | Essinger et al. | Aug 2019 | B2 |
10376680 | McNamara et al. | Aug 2019 | B2 |
10398421 | Celermajer | Sep 2019 | B2 |
10405903 | Biesinger et al. | Sep 2019 | B1 |
10413284 | McNamara et al. | Sep 2019 | B2 |
10413286 | McNamara et al. | Sep 2019 | B2 |
10463477 | Forcucci et al. | Nov 2019 | B2 |
10463490 | Rottenberg et al. | Nov 2019 | B2 |
10471251 | Manicka | Nov 2019 | B1 |
10478594 | Yacoby et al. | Nov 2019 | B2 |
10568751 | McNamara | Feb 2020 | B2 |
10588611 | Magnin et al. | Mar 2020 | B2 |
10610210 | Finch et al. | Apr 2020 | B2 |
10624621 | Celermajer | Apr 2020 | B2 |
10632292 | Forcucci et al. | Apr 2020 | B2 |
10639459 | Nitzan et al. | May 2020 | B2 |
10667896 | Delaney, Jr. et al. | Jun 2020 | B2 |
10675450 | Finch | Jun 2020 | B2 |
10828151 | Nitzan et al. | Nov 2020 | B2 |
10835394 | Nae et al. | Nov 2020 | B2 |
10898698 | Eigler | Jan 2021 | B1 |
10912645 | Rottenberg et al. | Feb 2021 | B2 |
10925706 | Eigler et al. | Feb 2021 | B2 |
10932786 | McNamara et al. | Mar 2021 | B2 |
10940296 | Keren | Mar 2021 | B2 |
10945716 | Chen et al. | Mar 2021 | B2 |
11135410 | Finch et al. | Oct 2021 | B2 |
11253685 | Fahey et al. | Feb 2022 | B2 |
11622695 | Andriola et al. | Apr 2023 | B1 |
11633194 | Alexander et al. | Apr 2023 | B2 |
11801369 | Fahey et al. | Oct 2023 | B2 |
11857197 | Alexander et al. | Jan 2024 | B2 |
20020072656 | Vantassel et al. | Jun 2002 | A1 |
20020142119 | Seward | Oct 2002 | A1 |
20020161427 | Rabkin et al. | Oct 2002 | A1 |
20020169371 | Gilderdale | Nov 2002 | A1 |
20020169475 | Gainor et al. | Nov 2002 | A1 |
20020177891 | Miles et al. | Nov 2002 | A1 |
20030125798 | Martin | Jul 2003 | A1 |
20030127090 | Gifford et al. | Jul 2003 | A1 |
20030163190 | LaFont et al. | Aug 2003 | A1 |
20040016514 | Nien | Jan 2004 | A1 |
20040077988 | Tweden et al. | Apr 2004 | A1 |
20040088045 | Cox | May 2004 | A1 |
20040093075 | Kuehne | May 2004 | A1 |
20040143294 | Corcoran et al. | Jul 2004 | A1 |
20040147869 | Wolf et al. | Jul 2004 | A1 |
20040158143 | Flaherty et al. | Aug 2004 | A1 |
20040162514 | Alferness et al. | Aug 2004 | A1 |
20040186566 | Hindrichs et al. | Sep 2004 | A1 |
20040210190 | Kohler et al. | Oct 2004 | A1 |
20040215067 | Stiger et al. | Oct 2004 | A1 |
20040215323 | Stiger | Oct 2004 | A1 |
20050004641 | Pappu | Jan 2005 | A1 |
20050033351 | Newton | Feb 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050101946 | Govari et al. | May 2005 | A1 |
20050148925 | Rottenberg et al. | Jul 2005 | A1 |
20050159789 | Brockway et al. | Jul 2005 | A1 |
20050165344 | Dobak, III | Jul 2005 | A1 |
20050192627 | Whisenant et al. | Sep 2005 | A1 |
20050204811 | Neff | Sep 2005 | A1 |
20050251212 | Kieval | Nov 2005 | A1 |
20050288722 | Eigler et al. | Dec 2005 | A1 |
20060009810 | Mann et al. | Jan 2006 | A1 |
20060025857 | Bergheim et al. | Feb 2006 | A1 |
20060047205 | Ludomirsky et al. | Mar 2006 | A1 |
20060064135 | Brockway | Mar 2006 | A1 |
20060111660 | Wolf et al. | May 2006 | A1 |
20060116625 | Renati et al. | Jun 2006 | A1 |
20060200030 | White et al. | Sep 2006 | A1 |
20070010837 | Tanaka | Jan 2007 | A1 |
20070010852 | Blaeser et al. | Jan 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070088220 | Stahmann | Apr 2007 | A1 |
20070088223 | Mann et al. | Apr 2007 | A1 |
20070112344 | Keilman | May 2007 | A1 |
20070118039 | Bodecker et al. | May 2007 | A1 |
20070150019 | Youker et al. | Jun 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070282157 | Rottenberg et al. | Dec 2007 | A1 |
20080033527 | Nunez et al. | Feb 2008 | A1 |
20080097276 | Bertrand et al. | Apr 2008 | A1 |
20080108904 | Heil | May 2008 | A1 |
20080119891 | Miles et al. | May 2008 | A1 |
20080127689 | McCusker et al. | Jun 2008 | A1 |
20080171941 | Huelskamp et al. | Jul 2008 | A1 |
20080208083 | Lin et al. | Aug 2008 | A1 |
20080208286 | Kieval | Aug 2008 | A1 |
20090025459 | Zhang et al. | Jan 2009 | A1 |
20090036975 | Ward et al. | Feb 2009 | A1 |
20090243956 | Keilman et al. | Oct 2009 | A1 |
20090270742 | Wolinsky et al. | Oct 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281597 | Parramon et al. | Nov 2009 | A1 |
20100063375 | Kassab et al. | Mar 2010 | A1 |
20100076366 | Henderson, Sr. et al. | Mar 2010 | A1 |
20100076517 | Imran | Mar 2010 | A1 |
20100106028 | Penner et al. | Apr 2010 | A1 |
20100168672 | Carr | Jul 2010 | A1 |
20100179449 | Chow et al. | Jul 2010 | A1 |
20100241241 | McKnight et al. | Sep 2010 | A1 |
20100249560 | Levinson et al. | Sep 2010 | A1 |
20100262021 | Yadav et al. | Oct 2010 | A1 |
20100262036 | Najafi et al. | Oct 2010 | A1 |
20100275592 | Topliss et al. | Nov 2010 | A1 |
20100298930 | Orlov | Nov 2010 | A1 |
20110054515 | Bridgeman et al. | Mar 2011 | A1 |
20110082377 | Mahajan et al. | Apr 2011 | A1 |
20110218480 | Rottenberg et al. | Sep 2011 | A1 |
20110218481 | Rottenberg et al. | Sep 2011 | A1 |
20110257723 | McNamara | Oct 2011 | A1 |
20110264194 | Griswold | Oct 2011 | A1 |
20110282217 | Nashet | Nov 2011 | A1 |
20110295183 | Finch et al. | Dec 2011 | A1 |
20120053686 | McNamara | Mar 2012 | A1 |
20120059431 | Williams et al. | Mar 2012 | A1 |
20120197392 | DuMoutelle et al. | Aug 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120229272 | Jacob et al. | Sep 2012 | A1 |
20120265296 | McNamara et al. | Oct 2012 | A1 |
20120283773 | Van Tassel et al. | Nov 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20130085350 | Schugt et al. | Apr 2013 | A1 |
20130123569 | Gross | May 2013 | A1 |
20130144379 | Najafi et al. | Jun 2013 | A1 |
20130178783 | Mcnamara et al. | Jul 2013 | A1 |
20130178784 | McNamara et al. | Jul 2013 | A1 |
20130190799 | Clark | Jul 2013 | A1 |
20130192611 | Taepke, II et al. | Aug 2013 | A1 |
20130197423 | Keren et al. | Aug 2013 | A1 |
20130211221 | Sunnarborg et al. | Aug 2013 | A1 |
20130253343 | Waldhauser et al. | Sep 2013 | A1 |
20130261531 | Gallagher et al. | Oct 2013 | A1 |
20130293025 | Xu et al. | Nov 2013 | A1 |
20140012342 | Penner et al. | Jan 2014 | A1 |
20140046427 | Michalak | Feb 2014 | A1 |
20140121750 | Hadley | May 2014 | A1 |
20140128795 | Karen et al. | May 2014 | A1 |
20140128796 | Keren et al. | May 2014 | A1 |
20140135647 | Wolf, II | May 2014 | A1 |
20140163449 | Rottenberg et al. | Jun 2014 | A1 |
20140213915 | Doan et al. | Jul 2014 | A1 |
20140213916 | Doan et al. | Jul 2014 | A1 |
20140213959 | Nitzan et al. | Jul 2014 | A1 |
20140222040 | Park et al. | Aug 2014 | A1 |
20140222144 | Eberhardt | Aug 2014 | A1 |
20140249616 | Strauss et al. | Sep 2014 | A1 |
20140277054 | McNamara et al. | Sep 2014 | A1 |
20140306807 | Rowland et al. | Oct 2014 | A1 |
20150034217 | Vad | Feb 2015 | A1 |
20150039084 | Levi | Feb 2015 | A1 |
20150084585 | Moran | Mar 2015 | A1 |
20150119796 | Finch | Apr 2015 | A1 |
20150141807 | Fetterly | May 2015 | A1 |
20150148731 | Mcnamara et al. | May 2015 | A1 |
20150157268 | Winshtein et al. | Jun 2015 | A1 |
20150208929 | Rowland et al. | Jul 2015 | A1 |
20150223707 | Ludoph et al. | Aug 2015 | A1 |
20150230843 | Palmer et al. | Aug 2015 | A1 |
20150231387 | Harding et al. | Aug 2015 | A1 |
20150287544 | Irazoqui et al. | Oct 2015 | A1 |
20160022423 | Mcnamara et al. | Jan 2016 | A1 |
20160089079 | Stein | Mar 2016 | A1 |
20160151179 | Favier et al. | Jun 2016 | A1 |
20160158561 | Reddy | Jun 2016 | A1 |
20160235999 | Nuta et al. | Aug 2016 | A1 |
20160302808 | Loganathan | Oct 2016 | A1 |
20160374682 | Leonard et al. | Dec 2016 | A1 |
20170014067 | Peppou et al. | Jan 2017 | A1 |
20170105635 | Cho et al. | Apr 2017 | A1 |
20170113026 | Finch | Apr 2017 | A1 |
20170312078 | Krivoruchko | Nov 2017 | A1 |
20170340460 | Rosen et al. | Nov 2017 | A1 |
20180014828 | Fonte et al. | Jan 2018 | A1 |
20180117341 | Kane et al. | May 2018 | A1 |
20180168463 | Morris et al. | Jun 2018 | A1 |
20180250014 | Melanson et al. | Sep 2018 | A1 |
20180256865 | Finch et al. | Sep 2018 | A1 |
20180262037 | Meskeus | Sep 2018 | A1 |
20180296375 | Van Langenhove | Oct 2018 | A1 |
20180310839 | McCaffrey et al. | Nov 2018 | A1 |
20190000327 | Doan | Jan 2019 | A1 |
20190014993 | Kaiser | Jan 2019 | A1 |
20190015103 | Sharma | Jan 2019 | A1 |
20190021861 | Finch | Jan 2019 | A1 |
20190150758 | Sailey et al. | May 2019 | A1 |
20190167197 | Abuuassar et al. | Jun 2019 | A1 |
20190173505 | Koyama | Jun 2019 | A1 |
20190175883 | Wessler et al. | Jun 2019 | A1 |
20190192864 | Koop et al. | Jun 2019 | A1 |
20190254814 | Nitzan | Aug 2019 | A1 |
20190262118 | Eigler | Aug 2019 | A1 |
20190269392 | Celermajer et al. | Sep 2019 | A1 |
20190298556 | Bohn et al. | Oct 2019 | A1 |
20190307459 | Celermajer et al. | Oct 2019 | A1 |
20190328513 | Levi et al. | Oct 2019 | A1 |
20190336135 | Inouye et al. | Nov 2019 | A1 |
20190336163 | McNamara et al. | Nov 2019 | A1 |
20190350519 | Bailey et al. | Nov 2019 | A1 |
20200008870 | Gruba et al. | Jan 2020 | A1 |
20200060825 | Rottenberg et al. | Feb 2020 | A1 |
20200078196 | Rosen et al. | Mar 2020 | A1 |
20200078558 | Yacoby et al. | Mar 2020 | A1 |
20200085600 | Schwartz et al. | Mar 2020 | A1 |
20200188143 | McNamara | Jun 2020 | A1 |
20200196867 | Andersen et al. | Jun 2020 | A1 |
20200196876 | Minor et al. | Jun 2020 | A1 |
20200197178 | Vecchio | Jun 2020 | A1 |
20200229977 | Mixter et al. | Jul 2020 | A1 |
20200229981 | Mixter et al. | Jul 2020 | A1 |
20200229982 | Mixter et al. | Jul 2020 | A1 |
20200245991 | Celermajer | Aug 2020 | A1 |
20200253615 | Melanson et al. | Aug 2020 | A1 |
20200260991 | Rowlaud et al. | Aug 2020 | A1 |
20200261705 | Nitzan et al. | Aug 2020 | A1 |
20200268515 | Vettukattil et al. | Aug 2020 | A1 |
20200281611 | Kelly | Sep 2020 | A1 |
20200315599 | Nae et al. | Oct 2020 | A1 |
20200368505 | Nae et al. | Nov 2020 | A1 |
20210030273 | Huang et al. | Feb 2021 | A1 |
20210038230 | Larsen et al. | Feb 2021 | A1 |
20210052378 | Nitzan et al. | Feb 2021 | A1 |
20210059527 | Najafi | Mar 2021 | A1 |
20210085935 | Fahey et al. | Mar 2021 | A1 |
20210100513 | Sahmauyar et al. | Apr 2021 | A1 |
20210100665 | Nae et al. | Apr 2021 | A1 |
20210121179 | Ben-david et al. | Apr 2021 | A1 |
20210145331 | Simpson et al. | May 2021 | A1 |
20210153776 | Minar et al. | May 2021 | A1 |
20210177508 | Kellerman | Jun 2021 | A1 |
20210205590 | Fahey et al. | Jul 2021 | A1 |
20210212638 | Golda et al. | Jul 2021 | A1 |
20210259732 | Dicicco et al. | Aug 2021 | A1 |
20210259829 | Quinn | Aug 2021 | A1 |
20210259839 | Cole et al. | Aug 2021 | A1 |
20210290214 | Cole et al. | Sep 2021 | A1 |
20210290356 | Srinkmann et al. | Sep 2021 | A1 |
20210298763 | Stahmann et al. | Sep 2021 | A1 |
20210299425 | Kume et al. | Sep 2021 | A1 |
20210299430 | Ratz et al. | Sep 2021 | A1 |
20210361238 | Bak-Boychuk et al. | Nov 2021 | A1 |
20210361257 | Eimer et al. | Nov 2021 | A1 |
20210370032 | Fahey et al. | Dec 2021 | A1 |
20210401418 | Dang et al. | Dec 2021 | A1 |
20220008014 | Rowe et al. | Jan 2022 | A1 |
20220039670 | Berrada et al. | Feb 2022 | A1 |
20220039671 | Fahey | Feb 2022 | A1 |
20220117555 | Zarbatauy et al. | Apr 2022 | A1 |
20220118228 | Fahey et al. | Apr 2022 | A1 |
20220142652 | Alexander et al. | May 2022 | A1 |
20220143368 | Pulugurtha | May 2022 | A1 |
20220151618 | Eigler et al. | May 2022 | A1 |
20220167861 | Stahmann | Jun 2022 | A1 |
20220184355 | Fahey et al. | Jun 2022 | A1 |
20220192677 | Wedul et al. | Jun 2022 | A1 |
20220218355 | Wedul et al. | Jul 2022 | A1 |
20220218964 | Fahey et al. | Jul 2022 | A1 |
20220226000 | Alexander et al. | Jul 2022 | A1 |
20220226623 | Fahey et al. | Jul 2022 | A1 |
20220240856 | Stahmann et al. | Aug 2022 | A1 |
20220265280 | Chamorro et al. | Aug 2022 | A1 |
20220313426 | Gifford, III | Oct 2022 | A1 |
20230056924 | Fox et al. | Feb 2023 | A1 |
20230084193 | Fahey et al. | Mar 2023 | A1 |
20230118243 | Fox et al. | Apr 2023 | A1 |
20230129883 | Andriola et al. | Apr 2023 | A1 |
20230158280 | Andriola et al. | May 2023 | A1 |
20230165672 | Fahey et al. | Jun 2023 | A1 |
20230191094 | Fahey et al. | Jun 2023 | A1 |
20230200667 | Andriola et al. | Jun 2023 | A1 |
20230201546 | Fahey et al. | Jun 2023 | A1 |
20230240852 | Fahey et al. | Aug 2023 | A1 |
20230371953 | Pantages et al. | Nov 2023 | A1 |
20230372683 | Andriola et al. | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
2005211243 | Aug 2005 | AU |
2010344182 | Aug 2012 | AU |
2011332324 | Jun 2013 | AU |
2012214279 | Aug 2013 | AU |
2018228451 | Sep 2019 | AU |
2785041 | Aug 2011 | CA |
2786575 | Aug 2011 | CA |
2818417 | May 2012 | CA |
2955389 | Jan 2016 | CA |
3054891 | Sep 2018 | CA |
101415452 | Apr 2009 | CN |
102458316 | May 2012 | CN |
102905626 | Jan 2013 | CN |
103458832 | Dec 2013 | CN |
105662653 | Jun 2016 | CN |
106456308 | Feb 2017 | CN |
109646063 | Apr 2019 | CN |
110536657 | Dec 2019 | CN |
1112044 | Jan 2007 | EP |
2097012 | Sep 2009 | EP |
2528646 | Dec 2012 | EP |
2642954 | Oct 2013 | EP |
2967867 | Jan 2016 | EP |
3087953 | Nov 2016 | EP |
3291773 | Mar 2018 | EP |
3300672 | Apr 2018 | EP |
3329860 | Jun 2018 | EP |
3579907 | Dec 2019 | EP |
3589238 | Jan 2020 | EP |
3624701 | Mar 2020 | EP |
2999412 | May 2020 | EP |
3705154 | Sep 2020 | EP |
3716877 | Oct 2020 | EP |
3740163 | Nov 2020 | EP |
3766431 | Jan 2021 | EP |
3834737 | Jun 2021 | EP |
3843618 | Jul 2021 | EP |
3871626 | Sep 2021 | EP |
3886761 | Oct 2021 | EP |
3893731 | Oct 2021 | EP |
3897369 | Oct 2021 | EP |
176973 | Dec 2006 | IL |
221127 | Sep 2012 | IL |
226374 | Jul 2013 | IL |
2115975 | Nov 2016 | IL |
227756 | Jun 2017 | IL |
220201 | Aug 2017 | IL |
253648 | Sep 2017 | IL |
255379 | Dec 2017 | IL |
252395 | Apr 2020 | IL |
2011KN04472 | Jul 2012 | IN |
2012KN01275 | Feb 2013 | IN |
2013KN01954 | Nov 2013 | IN |
2013CN06525 | Aug 2014 | IN |
2012KN01988 | Aug 2016 | IN |
2007527742 | Oct 2007 | JP |
2010508093 | Mar 2010 | JP |
2012196504 | Oct 2012 | JP |
2013046784 | Mar 2013 | JP |
2014503246 | Feb 2014 | JP |
2014512869 | May 2014 | JP |
2020509812 | Apr 2020 | JP |
20010046155 | Jun 2001 | KR |
WO99029227 | Jun 1999 | WO |
WO2003028522 | Apr 2003 | WO |
WO2005074367 | Aug 2005 | WO |
WO2007083288 | Jul 2007 | WO |
WO2008055301 | May 2008 | WO |
WO2010128501 | Nov 2010 | WO |
WO2010129089 | Nov 2010 | WO |
WO2011093941 | Aug 2011 | WO |
WO2011094521 | Aug 2011 | WO |
WO2012071075 | May 2012 | WO |
WO2012085913 | Jun 2012 | WO |
WO2012109557 | Aug 2012 | WO |
WO2013014539 | Jan 2013 | WO |
WO2013096965 | Jun 2013 | WO |
WO2014091222 | Jun 2014 | WO |
WO2014150106 | Sep 2014 | WO |
WO2014188279 | Nov 2014 | WO |
WO2016014821 | Jan 2016 | WO |
WO2016038115 | Mar 2016 | WO |
WO2016178171 | Nov 2016 | WO |
WO2018024868 | Feb 2018 | WO |
WO2018132549 | Jul 2018 | WO |
WO2018158747 | Sep 2018 | WO |
WO2019186101 | Feb 2019 | WO |
WO2019142152 | Jul 2019 | WO |
WO2019175401 | Sep 2019 | WO |
WO2019179447 | Sep 2019 | WO |
WO2019188917 | Oct 2019 | WO |
WO2019189079 | Oct 2019 | WO |
WO2019209420 | Oct 2019 | WO |
WO2020023514 | Jan 2020 | WO |
WO2020094085 | May 2020 | WO |
WO2020094087 | May 2020 | WO |
WO2020094094 | May 2020 | WO |
WO2020110048 | Jun 2020 | WO |
WO2020123338 | Jun 2020 | WO |
WO2020132678 | Jun 2020 | WO |
WO2020142515 | Jul 2020 | WO |
WO2020142613 | Jul 2020 | WO |
WO2020198694 | Oct 2020 | WO |
WO2020202046 | Oct 2020 | WO |
WO2020206366 | Oct 2020 | WO |
WO2020215090 | Oct 2020 | WO |
WO2020217194 | Oct 2020 | WO |
WO2020219265 | Oct 2020 | WO |
WO2020225698 | Nov 2020 | WO |
WO2020225757 | Nov 2020 | WO |
WO2020229636 | Nov 2020 | WO |
WO2020234751 | Nov 2020 | WO |
WO2020251700 | Dec 2020 | WO |
WO2020259492 | Dec 2020 | WO |
WO2021025905 | Feb 2021 | WO |
WO2021026485 | Feb 2021 | WO |
WO2021046753 | Mar 2021 | WO |
WO2021050589 | Mar 2021 | WO |
WO2021055264 | Mar 2021 | WO |
WO2021065873 | Apr 2021 | WO |
WO2021065874 | Apr 2021 | WO |
WO2021065875 | Apr 2021 | WO |
WO2021065912 | Apr 2021 | WO |
WO2021072315 | Apr 2021 | WO |
WO2021086707 | May 2021 | WO |
WO2021091566 | May 2021 | WO |
WO2021096766 | May 2021 | WO |
WO2021101707 | May 2021 | WO |
WO201126699 | Jun 2021 | WO |
WO2021113670 | Jun 2021 | WO |
WO2021136252 | Jul 2021 | WO |
WO2021136261 | Jul 2021 | WO |
WO2021138041 | Jul 2021 | WO |
WO2021146342 | Jul 2021 | WO |
WO2021150765 | Jul 2021 | WO |
WO2021158559 | Aug 2021 | WO |
WO2021159001 | Aug 2021 | WO |
WO2021162888 | Aug 2021 | WO |
WO2021178636 | Sep 2021 | WO |
WO2021190547 | Sep 2021 | WO |
WO2021212011 | Oct 2021 | WO |
WO2021216964 | Oct 2021 | WO |
WO2021217055 | Oct 2021 | WO |
WO2021217059 | Oct 2021 | WO |
WO2021224736 | Nov 2021 | WO |
WO2022046921 | Mar 2022 | WO |
WO2022076601 | Apr 2022 | WO |
WO2022081980 | Apr 2022 | WO |
WO2022103973 | May 2022 | WO |
WO2022192280 | Sep 2022 | WO |
WO2022266465 | Dec 2022 | WO |
WO2022266503 | Dec 2022 | WO |
WO2022272131 | Dec 2022 | WO |
WO2023278725 | Jan 2023 | WO |
Entry |
---|
http://www.collinsdictionary.com/dictionary/english/actuator. Accessed Oct. 18, 2023. |
https://www.ahdictionary.com/word/search.html?q=actuator. Accessed Oct. 18, 2023. |
https://www.dictionary.com/browse/Actuator. Accessed Oct. 18, 2023. |
International Search Report and Written Opinion received for International Application No. PCT/US22/19374, filed Mar. 8, 2022; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jun. 24, 2022; 11 pages. |
Jodi Perkins, “Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Clinical Trial to Leverage Novel Digital Endpoints,” Press Release, 2019 Copyright, Medical Alley Association, 3 pages. |
Lehner et al., “The Creation of an Interatrial Right-To-Left Shunt in Patients with Severe, Irreversible Pulmonary Hypertension: Rationale, Devices, Outcomes,” Current Cardiology Reports (2019) 21: 31, https://doi.org/10.1007/s11886-019-1118-8; 9 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US19/69106 filed Dec. 31, 2019; Applicant: Shifamed Holdings, LLC; Date of Mailing: Mar. 23, 2020; 10 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US20/49996 filed Sep. 9, 2020; Applicant: Shifamed Holdings, LLC; Date of Mailing: Feb. 17, 2021; 16 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US20/063360 filed Dec. 4, 2020; Applicant: Shifamed Holdings, LLC; Date of Mailing: Apr. 5, 2021; 13 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US20/64529 filed Dec. 11, 2020; Applicant: Shifamed Holdings, LLC; Date of Mailing: Apr. 8, 2021; 12 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US19/68354, filed Dec. 23, 2019; Applicant: Shifamed Holdings, LLC; Date of Mailing: Mar. 17, 2020; 11 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/16932, filed Feb. 5, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jun. 3, 2021; 11 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/14433, filed Jan. 21, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: May 14, 2021; 16 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/28926, filed Apr. 23, 2021 ; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jul. 22, 2021; 16 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US20/12059, filed Jan. 2, 2020; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jun. 5, 2020; 12 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US20/25509, filed Mar. 27, 2020; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jun. 25, 2020; 9 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US20/26738, filed Apr. 3, 2020; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jun. 30, 2020; 8 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/28931, filed Apr. 23, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: Sep. 24, 2021; 20 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/27747, filed Apr. 16, 2021 ; Applicant: Shifamed Holdings, LLC; Date of Mailing: Oct. 1, 2021; 16 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/53836, filed Oct. 6, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: Jan. 25, 2022; 20 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/47573, filed Aug. 25, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: Feb. 3, 2022; 15 pages. |
Kocaturk, O. et al., “Whole shaft visibility and mechanical performance for active MR catheters using copper-nitinol braided polymer tubes,” Journal of Cardiovascular Magnetic Resonance. Aug. 12, 2009, vol. 11, No. 29, pp. 9, col. 1, In 5-6. |
Hossain, M. et al. “In situ preparation of graphene-ZnO composites for enhanced graphite exfoliation and graphene-nylon-6 composite films,” Journal of Applied Polymer Science, Dec. 5, 2016, vol. 134, No. 27, p. 8, In 15-16,. |
International Search Report and Written Opinion received for International Application No. PCT/US21/55191, filed Oct. 15, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: Mar. 1, 2022; 12 pages. |
Anomet Products “Conductive Nitinol Wire” Aug. 15, 2020 (Aug. 15, 2020) Retrieved from website <URL: https://helpx.adobe.com/acrobat/using/allow-or-block-links-internet.html?mv=product&mv2=acrobat>, 4 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US21/58996, filed Nov. 11, 2021; Applicant: Shifamed Holdings, LLC; Date of Mailing: Feb. 7, 2022; 23 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US22/35764, filed Jun. 30, 2022; Applicant: Shifamed Holdings, LLC; Date of Mailing: Sep. 19, 2022; 10 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US22/34027, filed Jun. 17, 2022; Applicant: Shifamed Holdings, LLC; Date of Mailing: Oct. 25, 2022; 8 pages. |
International Search Report and Written Opinion received for International Application No. PCT/US22/34995, filed Jun. 24, 2022; Applicant: Shifamed Holdings, LLC; Date of Mailing: Nov. 18, 2022; 17 pages. |
Perk et al., “Catheter-based left atrial appendage occlusion procedure: role of echocardiography,” published on behalf of the European Society of Cardiology, Sep. 8, 2011, 7 pages. |
Collado et al, “Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation,” Journal of the American Heart Association, Jun. 2021, 18 pages. |
Ando et al., “Left ventricular decompression through a patent foramen ovale in a patient with hypertrophic cardiomyopathy: a case report,” Cardiovascular Ultrasound vol. Article No. 2 (2004). |
Braunwald, Heart Disease, Chapter 6, 2015, p. 186. |
Bridges et al., “The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization,” The Annals of Thoracic Surgery, vol. 77, Issue 4, Apr. 2004, pp. 1494-1502. |
Bristow et al., “Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure,” European Heart Journal, vol. 16, Issue suppl. F, Jul. 1995, pp. 20-31. |
Case et al., “Relief of High Left-Atrial Pressure in Left-Ventricular Failure,” Lancet, Oct. 17, 1964, pp. 841-842. |
Coats et al., “Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function,” Circulation, 1992;85:2119-2131. |
Davies et al., “Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure,” Circulation, (1995), 92:2540-2549, Circulation, (1995), 92:2540-2549. |
Ennezat et al., “An unusual case of low-flow, low gradient severe aortic stenosis: Left-to-right shunt due to atrial septal defect,” Cardiology, (2009), 113(2):146-148. |
Ewert et al., “Masked Left Ventricular Restriction in Elderly Patients With Atrial Septal Defects: a Contraindication for Closure,” Catheterization and Cardiovascular Interventions, 52: 177-180, 2001. |
Ewert et al., “Acute left heart failure after interventional occlusion of an atrial septal defect,” Z. Kardiol., Catheterization and Cardiovascular Interventions, Z. Kardiol., (May 2001), 90(5):362-366. |
Geiran et al., “Changes in cardiac dynamics by opening an interventricular shunt in dogs,” J. Surg. Res., (Jan. 1990), 48(1):6-12. |
Gelernter-Yaniv et al., “Transcatheter closure of left-to-right interatrial shunts to resolve hypoxemia,” Congenit. Heart Dis., (Jan. 2008), 31(1):47-53. |
Gewillig et al., “Creation with a stent of an unrestrictive lasting atrial communication,” Cardio. Young, (2002), 12(4):404-407. |
Khositseth et al., “Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical Embolism,” Mayo Clinic Proc., 79:35-41 (2004). |
Kramer et al., “Controlled study of captopril in chronic heart failure: a rest and exercise hemodynamic study,” Circulation, (1983), 67(4):807-816. |
Lai et al., “Bidirectional shunt through a residual atrial septal defect after percutaneous transvenous mitral commissurotomy,” Cardiology, (1993), 83(3):205-207. |
Lemmer et al., “Surgical implications of atrial septal defect complicating aortic balloon valvuloplasty,” Ann. thorac. Surg., (Aug. 1989), 48(2):295-297. |
Park et al., “Blade atrial septostomy: collaborative study,” Circulation, 66(2):258-266 (1982). |
Roven et al., “Effect of Compromising Right Ventricular Function in Left Ventricular Failure by Means of Interatrial and Other Shunts,” American Journal Cardiology, 24:209-219 (1969). |
Salehian et al., “Improvements in Cardiac Form and Function After Transcatheter Closure of Secundum Atrial Septal Defects,” Journal of the American College of Cardiology, 45(4):499-504 (2005). |
Schmitto et al., “Chronic heart failure induced by multiple sequential coronary microembolization in sheep,” The International Journal of Artificial Organs, 31(4):348-353 (2008). |
Schubert et al., “Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of the atrial septal defect,” Catheter Cardiovasc. Interv., (2005), 64(3):333-337. |
Stormer et al., “Comparative study of in vitro flow characteristics between a human aortic valve and a designed aortic and six corresponding types of prosthetic heart valves,” European Surgical Research, (1976), 8(2):117-131. |
Stumper et al., “Modified technique of stent fenestration of the atrial septum, Heart,” (2003), 89:1227-1230. |
Trainor et al., “Comparative Pathology of an Implantable Left Atrial Pressure Sensor,” ASAIO Journal, Clinical Cardiovascular/Cardiopulmonary Bypass, 59(5):486-92 (2013). |
Zhou et al., “Unidirectional valve patch for repair of cardiac septal defects with pulmonary hypertension,” Annals of Thoracic Surgeons, 60: 1245-1249, 1995. |
Extended European Search Report received for Application No. 20896031.0, Applicant: Shifamed Holdings, LLC; Date of Mailing: Dec. 7, 2023; 11 pages. |
Huang et al., “Shape Memory Materials,” Science Direct, Materials Today, vol. 13, Sep. 1, 2010, 15 pages. |
Retrieved from the Internet:URL:https://www.sciencedirect.com/science/article/pii/S1369702110701280#bib1, retrieved on Jan. 22, 2024, 1 page. |
Extended European Search Report received for Application No. 21791938.0, Applicant: Shifamed Holdings, LLC; Date of Mailing: Apr. 3, 2024; 6 pages. |
Number | Date | Country | |
---|---|---|---|
20230201545 A1 | Jun 2023 | US |
Number | Date | Country | |
---|---|---|---|
63158508 | Mar 2021 | US |